Pancreatic Necrosectomy

Pancreatic necrosectomy is debridement of devitalized pancreatic and peripancreatic tissue in patients with necrotizing pancreatitis. The principal indication is infected pancreatic necrosis, manifesting as clinical deterioration (worsening sepsis, organ failure) in a patient with established pancreatic necrosis, usually 2–4 weeks into the course of the illness. Demonstration of gas in the necrotic collection on CT, or positive culture from image-guided aspiration, confirms infection. The other indication is persistent symptomatic sterile walled-off necrosis at >4–8 weeks — typically pain, gastric outlet obstruction, biliary obstruction, or persistent organ dysfunction — that has not improved with supportive care.

The contemporary discipline is patience. Sterile necrosis is managed nonoperatively with bowel rest, nutrition (preferring enteral if tolerated), antibiotics only when infection is documented (not prophylactically), and ICU support. Intervention is deferred for as long as possible, ideally until ≥4 weeks from onset, to allow the necrosis to demarcate and a fibrous wall (walled-off necrosis or 'WON') to form. Early operation on inflamed, undemarcated necrosis bleeds heavily, removes viable tissue alongside dead tissue, and carries unacceptable mortality.

The PANTER trial (van Santvoort and colleagues, NEJM 2010) established the contemporary standard. Eighty-eight patients with necrotizing pancreatitis and suspected or confirmed infected necrosis were randomized to primary open necrosectomy versus a step-up approach (percutaneous catheter drainage first, followed by minimally invasive retroperitoneal necrosectomy if drainage was inadequate). The step-up approach produced lower rates of the composite primary endpoint (major complications or death — 40% vs 69%) and lower mortality. Subsequent endoscopic and surgical variations have refined the technique, but the step-up principle — escalate only when the previous step fails — has remained.

The first step is percutaneous catheter drainage of the largest accessible collection, typically a 14-French or larger pigtail catheter placed under CT or ultrasound guidance through a left retroperitoneal flank approach (chosen to allow subsequent surgical access through the same tract). Drainage of pus and necrotic debris through the catheter, with daily flushing, will resolve the clinical picture in approximately one-third to one-half of patients without further intervention.

If clinical deterioration persists or drainage is inadequate after 72–96 hours, the second step is escalation to debridement. Two approaches are common today: video-assisted retroperitoneal debridement (VARD), in which the existing drain tract is dilated and a flexible endoscope or laparoscope is introduced retroperitoneally to debride necrotic material under direct vision; or endoscopic transgastric necrosectomy, in which a lumen-apposing metal stent is placed between the stomach and the walled-off necrosis under endoscopic ultrasound guidance, and subsequent endoscopic sessions debride necrotic material into the stomach. Endoscopic and surgical step-up approaches show similar outcomes in trials. Open transperitoneal necrosectomy is reserved for failure of these less-invasive techniques and for patients with anatomy unfavorable to retroperitoneal or endoscopic access.

Whether retroperitoneal, endoscopic, or open, the operative principles are identical and fundamental. First: necrosectomy is debridement, not resection. Viable pancreas should be preserved; only loose, necrotic tissue is removed. Aggressive sharp dissection bleeds heavily and removes viable tissue inappropriately. Necrotic tissue is removed in pieces with blunt or gentle sharp technique — the operative phrase is 'finger fracture' debridement.

Second: bleeding control is critical. The splenic artery and vein run along the superior border of the pancreas, and the splenic artery is particularly vulnerable to pseudoaneurysm in the inflamed peripancreatic tissue. Significant bleeding during necrosectomy mandates packing, angiographic embolization (preferred for splenic artery pseudoaneurysm), or, rarely, ligation. Third: large-bore drainage of the cavity is essential. Whether retroperitoneal drains, transgastric stents, or open packing, the cavity must drain so that residual necrotic material can be evacuated and infection cleared.

Fourth: necrosectomy is rarely complete in a single session. Multiple debridements over weeks are expected. The patient is taken back for repeat necrosectomy, drain upsize, or drain re-positioning until the cavity collapses and clinical improvement is sustained.

Postoperative ICU care is the rule. Antibiotics are continued for documented infection (carbapenems or piperacillin-tazobactam are commonly used initially, narrowed to culture-guided coverage). Enteral nutrition — via nasojejunal tube or feeding jejunostomy — is preferred over total parenteral nutrition when tolerated, because it preserves gut barrier function and reduces infectious complications. Drain output is monitored closely, with amylase measured if a pancreatic fistula is suspected. Repeat CT at intervals tracks resolution of the cavity and identifies new collections.

Recovery is measured in weeks to months. Hospital stay after a necrosectomy course is typically 4–8 weeks. Late issues include pancreatic exocrine and endocrine insufficiency (the loss of functional pancreas is permanent), pancreatic fistula (managed conservatively with drainage and somatostatin analogs; refractory fistulas may require distal pancreatectomy or fistulojejunostomy), and recurrence.

Major complications and death remain frequent despite the step-up approach. Hemorrhage from peripancreatic vessels — most commonly the splenic artery, but also gastroduodenal and pancreaticoduodenal arteries — can be catastrophic. Suspected bleeding is managed initially by angiography and embolization rather than reoperation, because operative control in an inflamed, friable retroperitoneum is hazardous. Pancreatic fistula is essentially universal after necrosectomy and is managed with continued drainage; persistent high-output fistulas may require ERCP with pancreatic stent placement or operative pancreatic resection.

Enteric fistula (most commonly colonic or duodenal) from inflammation of bowel adjacent to the necrotic cavity occurs in 5–10% and may require fecal diversion (colostomy or ileostomy). Recurrent infection requires repeat debridement or drain manipulation. Late complications include diabetes mellitus, exocrine insufficiency (with steatorrhea and weight loss, managed with pancreatic enzyme replacement), incisional hernia, and chronic disability. Long-term mortality is non-trivial, particularly in elderly or severely deconditioned patients.

On the oral boards, examiners typically test: when and why to wait at least 4 weeks before intervention; the indication for intervention (infection or persistent symptoms — not the mere presence of necrosis); the step-up principle established by the PANTER trial; the sequence of percutaneous drainage → minimally invasive (VARD or endoscopic transgastric) → open as a last resort; the principle that necrosectomy is debridement, not resection; recognition and management of splenic artery pseudoaneurysm; and the expected long-term sequelae of exocrine and endocrine insufficiency.